Helios Underwriting plc (HUW.L)
London, GB
Helios Underwriting plc offers its shareholders a means of limited liability investment within the distinguished Lloyd's insurance market in the United Kingdom. The company's operations are divided into three principal areas: Syndicate Participation, Investment Management, and various Other Corporate Activities. Its involvement in the Lloyd's market is primarily managed through a diverse array of Lloyd's syndicates, which focus on delivering property insurance and reinsurance solutions. Founded in 2006 and headquartered in London, UK, the firm was formerly known as Hampden Underwriting Plc before adopting its current name in January 2014.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.95% | +0.47% | +0.00% | -1.61% | +1.18% | +3.64% | -4.69% | +23.77% | +33.45% | +20.11% | +120.28% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Insurance - Property & Casualty: +14.1%-96.4% Q4'25: -99.4% (vs Q4'23)
-
EPS growth Insurance - Property & Casualty: +27.5%+12.0% Q4'25: +46.7% (vs Q4'23)
-
FCF margin FCF growth · Insurance - Property & Casualty: +25.6%+3,721.7% ★ Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Insurance - Property & Casualty: +16.3%+2,067.0% ★ Q4'25: +2,768.0% (vs Q4'23)
-
ROIC Insurance - Property & Casualty: +7.9%+13.1% ★ Q4'25: +38.6% (vs Q4'23)
-
Share dilution Insurance - Property & Casualty: +0.4%-2.0% ★ Q4'25: -6.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Insurance - Property & Casualty: -0.10×2.01× Q4'25: 0.69× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
25.93M
est: 2.35M (+1,003.3%)
|
30.67M
est: 1.72M (+1,683.0%)
|
31.33M
est: 1.77M (+1,668.0%)
|
45.22M
est: 2.63M (+1,616.6%)
|
52.30M
est: 1.23M (+4,148.3%)
|
70.58M
est: 76.14M (-7.3%)
|
149.39M
est: 137.61M (+8.6%)
|
209.36M
est: 254.34M (-17.7%)
|
36.00M
est: 328.07M (-89.0%)
|
1.31M
est: 30.20M (-95.7%)
|
38.60M
38.60M – 38.60M
+27.8% YoY
|
35.80M
35.80M – 35.80M
-7.3% YoY
|
| EBITDA |
—
est: 392.8K (-100.0%)
|
—
est: 287.5K (-100.0%)
|
1.34M
est: 296.2K (+352.7%)
|
3.29M
est: 440.3K (+646.3%)
|
-746.0K
est: 205.8K (-462.5%)
|
868.0K
est: 12.73M (-93.2%)
|
-4.21M
est: 23.00M (-118.3%)
|
24.30M
est: 94.11M (-74.2%)
|
26.99M
est: 121.39M (-77.8%)
|
27.02M
est: 11.17M (+141.8%)
|
14.28M
14.28M – 14.28M
+27.8% YoY
|
13.25M
13.25M – 13.25M
-7.3% YoY
|
| EBIT |
—
est: 388.5K (-100.0%)
|
—
est: 284.3K (-100.0%)
|
—
est: 292.9K (-100.0%)
|
4.29M
est: 435.4K (+884.6%)
|
-746.0K
est: 203.5K (-466.6%)
|
-571.0K
est: 12.59M (-104.5%)
|
-2.99M
est: 22.75M (-113.1%)
|
24.92M
est: 93.63M (-73.4%)
|
26.99M
est: 120.78M (-77.7%)
|
27.02M
est: 11.12M (+143.0%)
|
14.21M
14.21M – 14.21M
+27.8% YoY
|
13.18M
13.18M – 13.18M
-7.3% YoY
|
| Net Income |
713.0K
est: 5.90M (-87.9%)
|
-694.0K
est: -2.24M (+69.0%)
|
456.0K
est: 3.81M (-88.0%)
|
4.05M
est: 2.85M (+42.1%)
|
301.0K
est: -379.1K (+179.4%)
|
-434.0K
est: 341.2K (-227.2%)
|
-2.10M
est: -909.9K (-130.9%)
|
16.37M
est: 17.61M (-7.0%)
|
18.58M
est: 14.37M (+29.2%)
|
20.55M
est: 24.78M (-17.1%)
|
29.39M
29.39M – 29.39M
+18.6% YoY
|
26.15M
26.15M – 26.15M
-11.0% YoY
|
| SGA |
10.82M
est: 789.7K (+1,269.9%)
|
11.82M
est: 578.0K (+1,944.7%)
|
11.70M
est: 595.5K (+1,864.1%)
|
15.76M
est: 885.2K (+1,680.9%)
|
17.92M
est: 413.7K (+4,230.8%)
|
25.41M
est: 25.59M (-0.7%)
|
53.83M
est: 46.24M (+16.4%)
|
84.16M
est: 68.05M (+23.7%)
|
7.76M
est: 87.77M (-91.2%)
|
—
est: 8.08M (-100.0%)
|
10.33M
10.33M – 10.33M
+27.8% YoY
|
9.58M
9.58M – 9.58M
-7.3% YoY
|
| EPS |
0.06
est: 0.08 (-20.0%)
|
-0.05
est: -0.03 (-60.9%)
|
0.03
est: 0.05 (-37.4%)
|
0.25
est: 0.04 (+564.2%)
|
0.02
est: -0.01 (+416.0%)
|
-0.01
est: 0.00 (-266.7%)
|
-0.03
est: -0.01 (-156.7%)
|
0.22
est: 0.24 (-7.2%)
|
0.26
est: 0.19 (+34.4%)
|
0.29
est: 0.33 (-13.0%)
|
0.40
0.40 – 0.40
+18.6% YoY
|
0.35
0.35 – 0.35
-11.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adhiraj Maitra | Chief Financial Officer & Executive Director | — | male |
| David Shawe | Finance Controller | — | male |
| Jen Tan | Chief Underwriting Officer | — | female |
| Louis George De Normanville Tucker | Chief Executive Officer & Director | — | male |
| Reva Jain | Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HUW.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
